The Aim of This Investigation is to Compare the Influence of 0.9% Saline and Plasmalyte Solution on Acid-base Balance and Electrolytes in Healthy Patients Undergoing Major Spine Surgeries.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01855542

Enrollment

Registered

2013-05-16

Start date

2012-03-31

Completion date

2013-01-31

Last updated

2013-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spinal Surgery

Keywords

metabolic acidosis, plasmalyte solution, 0.9% normal saline

Brief summary

Chloride-rich isotonic crystalloid solutions have been shown to exert electrolyte imbalance and metabolic acidosis in critically ill patients. The aim of this investigation is to compare the influence of 0.9% saline and plasmalyte solution on acid-base balance and electrolytes in healthy patients undergoing major spine surgeries.

Interventions

OTHER0.9% normal saline

In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.

OTHERplasmalyte

In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Yes

Inclusion criteria

1.50 patients (aged 20-65) undergoing cervical or lumbar spine surgery who were diagnosed spinal stenosis involving more than tow spinal levels.

Exclusion criteria

1. ASA class III or IV 2. pregnancy 3. breast feeding 4. lack of mental weakness(including disabled) 5. using diuretics 6. respiratory insufficiency 7. metabolic acidosis or alkalosis 8. coagulation disorder 9. over hydtration 10. renal failure or serum creatinine \> 1.4mg/dl 11. anemia (Hemoglobin 9.0\<mg/dl) 12. hypernatremia (Na \> 145mEq/L) 13. Hyperkalemia (K\>5.5mEq/L) 14. psychological medication or any drugs that influences renal clearance

Design outcomes

Primary

Measure	Time frame
base-excess	Change from baseline in base-excess at postoperative 12 h

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026